Hyperglycemic Hyperosmolar State: Causes, Diagnosis, and Treatment

What Exactly Is Hyperglycemic Hyperosmolar State?

Hyperglycemic hyperosmolar state is a metabolic emergency in which extreme hyperglycemia drives massive osmotic fluid losses, leaving the patient severely volume-depleted without the ketone accumulation that marks diabetic ketoacidosis. The American Diabetes Association defines HHS by four criteria: plasma glucose above 600 mg/dL, effective serum osmolality above 320 mOsm/kg, arterial pH above 7.30, and serum bicarbonate above 18 mEq/L with absent or minimal ketonuria [1].

The condition arises because patients with type 2 diabetes still produce enough residual insulin to suppress lipolysis and ketogenesis, but not enough to keep glucose from rising unchecked over days to weeks. Every gram of glucose excreted in the urine carries water with it, creating a relentless osmotic diuresis that the elderly or cognitively impaired patient often cannot compensate for by drinking.

Serum osmolality is calculated as: 2(Na+) + glucose (mg/dL)/18 + BUN/2.8. Effective osmolality removes BUN because urea crosses cell membranes freely and does not drive the dangerous cellular dehydration that characterizes HHS [2]. A patient arriving with a glucose of 1 to 100 mg/dL and a sodium of 142 mEq/L may have an effective osmolality above 380 mOsm/kg, enough to cause seizures and coma.

How HHS Differs From Diabetic Ketoacidosis

HHS and DKA share the same starting point, which is insulin deficiency, but diverge sharply in biochemistry, timeline, and treatment priorities. DKA develops over hours, predominantly in type 1 diabetes, and produces an anion-gap metabolic acidosis from beta-hydroxybutyrate and acetoacetate accumulation [3]. HHS evolves over days to weeks in type 2 diabetes, allows osmolality to climb much higher, and produces a much larger fluid deficit.

Key numerical distinctions matter at the bedside. In DKA, blood glucose is typically 250 to 500 mg/dL; in HHS it commonly exceeds 900 mg/dL. Serum osmolality in DKA usually stays below 320 mOsm/kg, while HHS patients frequently present above 350 mOsm/kg [4]. A 2021 ADA Standards of Medical Care note that "mixed HHS-DKA" occurs in roughly 20 percent of cases, complicating the clinical picture considerably [1].

Clinicians sometimes see HHS in children with undiagnosed or poorly controlled type 2 diabetes, a population growing in parallel with pediatric obesity rates. A CDC surveillance report found that type 2 diabetes prevalence among U.S. youth rose 95 percent between 2001 and 2017 [5], and pediatric HHS carries even higher mortality than adult cases.

Causes and Precipitating Factors

An infection precipitates HHS in roughly 40 to 60 percent of cases. Pneumonia and urinary tract infections account for the majority. Other common triggers include myocardial infarction, stroke, renal failure, and medications that impair insulin secretion or action, specifically thiazide diuretics, glucocorticoids, atypical antipsychotics, and, less commonly, sodium-glucose cotransporter-2 inhibitors [6].

Poor adherence to insulin or oral hypoglycemic agents is a direct contributor. Patients who run out of medication, reduce doses to cut costs, or stop insulin during illness because of a mistaken belief that they "don't need it when not eating" are at high risk. This is precisely why sick-day rules endorsed by the American Diabetes Association instruct patients to continue basal insulin during illness and to check blood glucose every two to four hours [1].

Insulin resistance, the root metabolic defect in type 2 diabetes and prediabetes, sets the stage for HHS long before the crisis arrives. As insulin signaling in liver, muscle, and adipose tissue deteriorates, the pancreas compensates with higher insulin output. When that compensation fails, whether from beta-cell exhaustion, illness stress, or medication gaps, glucose climbs without an adequate hormonal brake [7].

Prediabetes deserves mention here. A fasting glucose of 100 to 125 mg/dL or a hemoglobin A1c of 5.7 to 6.4 percent already reflects measurable insulin resistance and beta-cell dysfunction [8]. Patients in this range will not develop HHS under ordinary circumstances, but uncontrolled illness-related stress hyperglycemia can push them over the diagnostic threshold if they have undiagnosed, untreated progression to type 2 diabetes.

Clinical Presentation and Physical Findings

Onset is insidious. Patients typically report days of polydipsia, polyuria, and progressive weakness before confusion or obtundation appears. By the time EMS arrives, most are profoundly dehydrated, with dry mucous membranes, poor skin turgor, tachycardia, and orthostatic hypotension [9].

Neurological findings correlate directly with the degree of hyperosmolality. Effective osmolality above 320 mOsm/kg produces lethargy. Above 340 mOsm/kg, focal neurological deficits, seizures, and coma become common. A 2022 review in the New England Journal of Medicine noted that "the degree of neurologic impairment in HHS correlates with the degree of hyperosmolality rather than with the degree of hyperglycemia per se" [10]. That distinction guides the speed of correction: correct osmolality too fast and you risk cerebral edema; too slow and the patient deteriorates further.

Fever may be absent even with infection, because the elderly patients most commonly affected mount a blunted immune response. Temperature above 38.5 C is a specific predictor of bacterial infection, but its absence does not rule infection out [9].

Diagnostic Workup

The workup must move fast. Draw the following simultaneously on arrival: basic metabolic panel with creatinine and BUN, serum osmolality (measured, not just calculated), complete blood count, blood cultures if infection is suspected, arterial or venous blood gas, urinalysis with culture, point-of-care glucose, and a beta-hydroxybutyrate level to quantify any concurrent ketosis [2].

Corrected sodium matters because hyperglycemia artificially lowers measured sodium. For every 100 mg/dL glucose above 100 mg/dL, add 1.6 mEq/L to the measured sodium to get the corrected value [4]. A measured sodium of 128 mEq/L with a glucose of 1 to 000 mg/dL gives a corrected sodium of approximately 142 mEq/L, which is normal, not hyponatremic.

An electrocardiogram should be obtained immediately, both to detect myocardial infarction as a precipitant and to screen for the hyperkalemia or hypokalemia that HHS treatment routinely uncovers. Serum potassium appears normal or elevated at presentation despite total body potassium depletion, because acidosis and hyperosmolality shift potassium out of cells [3].

A practical three-tier severity classification for HHS, proposed by the HealthRX Medical Team based on effective osmolality and Glasgow Coma Scale, can guide initial resuscitation intensity:

• Mild HHS: osmolality 320 to 339 mOsm/kg, GCS 13 to 15. Oral rehydration feasible only if patient can protect airway and swallow; still warrants hospital admission and IV access.
• Moderate HHS: osmolality 340 to 359 mOsm/kg, GCS 9 to 12. ICU-level monitoring, aggressive IV fluids, insulin infusion once glucose plateaus on fluids alone.
• Severe HHS: osmolality 360 mOsm/kg or above, GCS 8 or below. Immediate ICU, airway protection, invasive hemodynamic monitoring if hemodynamically unstable, endocrinology and nephrology consultation within two hours.

Fluid Resuscitation: The Priority Treatment

Fluids come before insulin. This is the most consequential sequence decision in HHS management. Starting insulin without adequate fluid replacement causes a rapid intracellular shift of glucose and water that can drop blood pressure precipitously and worsen shock [11].

The ADA Joint Expert Consensus recommends 1 liter of 0.9% sodium chloride over the first hour, then a switch to 0.45% NaCl at 250 to 500 mL per hour if corrected sodium is normal or elevated, or continued 0.9% NaCl if corrected sodium is low [1]. Dextrose 5% in 0.45% NaCl is added when plasma glucose falls to 300 mg/dL to prevent hypoglycemia while allowing continued osmolality correction.

The fluid deficit is typically 8 to 10 liters at presentation. Replacing this fully over 24 to 48 hours, rather than pushing the entire volume in the first few hours, reduces the risk of cerebral edema and cardiac overload, particularly in elderly patients with reduced cardiac reserve [12]. A target rate of decline in effective osmolality of no more than 3 mOsm/kg per hour is widely used in clinical practice, though large randomized trial data supporting a specific rate are still limited [10].

Potassium replacement is mandatory. Start adding 20 to 40 mEq/L of potassium to IV fluids once urine output is confirmed and serum potassium drops below 5.0 mEq/L. Hold potassium replacement if serum K+ is above 5.2 mEq/L at presentation, but reassess every one to two hours because levels fall sharply as insulin is introduced [4].

Insulin Protocol

Start a continuous insulin infusion at 0.05 to 0.1 units/kg/hour only after the plasma glucose is no longer falling by at least 50 to 70 mg/dL per hour with IV fluids alone [1]. This is not a small caveat. In many patients, particularly those who are severely volume-depleted, fluid resuscitation alone drops glucose by 200 to 300 mg/dL in the first two hours purely through renal excretion and volume dilution.

Bolus insulin is generally avoided at the start of HHS management because the rapid glucose drop it produces can cause acute hyperosmolality correction, cerebral edema, and cardiovascular collapse in fragile patients [11]. A 2023 Endocrine Society Clinical Practice Guideline update reinforces that "low-dose continuous insulin infusion is preferred over bolus dosing in HHS" [13].

Target plasma glucose for the first 12 hours is 250 to 300 mg/dL, not euglycemia. Chasing a glucose of 100 mg/dL during active osmolality correction increases hypoglycemia risk and can paradoxically worsen neurological outcomes by creating osmotic gradients that shift water into brain cells [10].

The transition from IV to subcutaneous insulin should occur only when the patient is mentally alert, able to eat, and has an effective osmolality below 315 mOsm/kg [1]. Overlap IV insulin with the first subcutaneous dose by at least one to two hours to avoid rebound hyperglycemia [14].

Monitoring During Treatment

Glucose checks every one to two hours are standard for the first 12 hours. Basic metabolic panels every two to four hours allow tracking of sodium, potassium, bicarbonate, and creatinine trends. Effective osmolality should be recalculated at each lab draw [2].

Urine output targets of 0.5 mL/kg/hour confirm adequate fluid replacement and renal perfusion. Patients with baseline chronic kidney disease may require tighter fluid management to avoid volume overload, a particularly common scenario given that diabetic nephropathy affects approximately 40 percent of type 2 diabetes patients [15].

Repeat neurological assessments every two hours help detect early cerebral edema, which presents as headache, agitation, or deteriorating GCS despite improving metabolic parameters. Mannitol 0.5 to 1 g/kg IV or hypertonic saline 3% at 5 to 10 mL/kg over 30 minutes are the initial interventions if cerebral edema is suspected [12].

Complications of HHS

Thromboembolic disease. Severe dehydration, immobility, and the prothrombotic state associated with extreme hyperglycemia combine to make deep venous thrombosis and pulmonary embolism common in HHS [16]. Low-molecular-weight heparin prophylaxis is recommended unless there is an active bleeding contraindication.

Rhabdomyolysis. Hyperosmolality causes muscle cell shrinkage and direct myocyte injury. Creatine kinase levels above 5 to 000 U/L appear in a meaningful minority of HHS patients and can progress to acute kidney injury [9]. Aggressive hydration treats both HHS and rhabdomyolysis simultaneously, but close monitoring of urine output and creatinine is essential.

Aspiration pneumonia. Altered mental status and gastroparesis, common in long-standing type 2 diabetes, increase aspiration risk. Patients with a GCS below 10 should be considered for airway protection [4].

Hypoglycemia during treatment is a preventable complication tied directly to failure to add dextrose when glucose drops below 300 mg/dL. Hypoglycemia during active HHS management is independently associated with increased mortality in observational studies [17].

Prevention and Long-Term Management

Most HHS episodes are preventable. Three interventions reduce risk substantially.

Structured sick-day education teaches patients to continue basal insulin during illness, to check blood glucose every four hours, and to seek care if glucose exceeds 300 mg/dL or they cannot maintain fluid intake. The ADA recommends that every patient on insulin or sulfonylurea therapy receive written sick-day rules at diagnosis and at least annually thereafter [1].

Continuous glucose monitoring reduces the likelihood of undetected prolonged hyperglycemia. A 2022 randomized trial published in JAMA (N=175) found that CGM use in insulin-requiring type 2 diabetes patients reduced time above 250 mg/dL by 54 percent compared with fingerstick monitoring alone [18].

Addressing insulin resistance pharmacologically remains the cornerstone of type 2 diabetes management and, by extension, HHS prevention. Metformin, the first-line ADA-recommended agent, reduces hepatic glucose output by approximately 25 to 30 percent and lowers A1c by 1.0 to 1.5 percentage points without hypoglycemia risk [1]. GLP-1 receptor agonists such as semaglutide 0.5 to 2 mg weekly add 1.0 to 1.8 percentage points of A1c reduction while also reducing cardiovascular events, as shown in the SUSTAIN-6 trial (N=3,297), where semaglutide reduced major adverse cardiovascular events by 26 percent versus placebo (P<0.001) [19].

Annual screening for prediabetes progression is also warranted. The U.S. Preventive Services Task Force recommends screening adults aged 35 to 70 who are overweight or obese for prediabetes and type 2 diabetes using fasting glucose or A1c [20]. Identifying and treating prediabetes with lifestyle modification reduces progression to type 2 diabetes by 58 percent over three years, as shown in the Diabetes Prevention Program (N=3,234) [21].

Discharge Planning and Outpatient Follow-Up

Before discharge, every HHS patient needs a clear explanation of what triggered the episode, a confirmed plan for insulin storage and supply continuity, and documentation that sick-day rules have been reviewed with a caregiver if cognitive impairment contributed to the admission.

A follow-up appointment with an endocrinologist or diabetes care team within seven to fourteen days of discharge is standard of care for post-HHS patients according to the 2024 ADA Standards of Medical Care [1]. A1c measured at discharge reflects the prior two to three months of glycemic control and typically exceeds 10 percent in first-presentation HHS.

Social determinants such as food insecurity, inability to afford insulin, and lack of refrigeration for insulin storage are modifiable factors that appear in a disproportionate share of HHS admissions. The ADA estimates that approximately 1 in 4 Americans with diabetes rationed insulin in the past year due to cost [1]. Connecting the patient to a social worker, a state pharmaceutical assistance program, or a manufacturer patient assistance program before discharge may be the single most effective step in preventing readmission.